FTL and hepatocellular carcinoma: The combination of artesunate and hepatocellular carcinoma advanced first-line drug sorafenib induces oxidative stress and ferritinophagy in hepatocellular carcinoma cells and promotes lysosome-dependent FTL degradation to improve the efficacy of single drug [89].